A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Trial Profile

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Cemiplimab (Primary) ; Carboplatin; Cyclophosphamides; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2017 Last checked against ClinicalTrials.gov record.
    • 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2017 Preliminary results from patients with advanced cutaneous squamous cell carcinoma (n=26) published in a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top